Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544283 | 0.78 | MIF (0.37) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL18653330 | 0.77 | MEN1 (0.33) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL16471295 | 0.74 | KMT2A (0.30) | KMT2A | |
| SCHEMBL16478056 | 0.72 | TRPV4 (0.52) | MAPK1 | |
| SCHEMBL952362 | 0.72 | ALDH1A1 (0.45) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL16478249 | 0.72 | HTR3E (0.48) | ALDH1A1CYP3A4HPGDMAPK1 | |
| SCHEMBL16478250 | 0.70 | HTR3E (0.31) | — | |
| SCHEMBL15850516 | 0.70 | VCAM1 (0.40) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL1811343 | 0.69 | ALDH1A1 (0.38) | MEN1ALDH1A1TP53CYP3A4MAPT | |
| SCHEMBL16478063 | 0.69 | GRIN2D (0.31) | MEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2870143-B1 | TRIAZOLE COMPOUNDS AS ANTIVIRALS | HOFFMANN LA ROCHE (CH) | 2017-05-17 | — | — | EP | disclosed |
| EP-2964637-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2017-04-12 | — | — | EP | disclosed |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2017-03-23 | — | — | US | disclosed |
| US-9428469-B2 | Antiviral compounds | HOFFMANN-LA ROCHE (US) | 2016-08-30 | — | — | US | disclosed |
| US-20160009666-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2016-01-14 | — | — | US | disclosed |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. (US) | 2015-10-29 | — | — | US | disclosed |
| WO-2014135471-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| WO-2014135422-A1 | ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-09-12 | — | — | WO | disclosed |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HOFFMANN-LA ROCHE INC. | 2014-01-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160009666-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | MEN1 4614/4885ALDH1A1 206/4885TP53 2965/4885 |
| US-20170081312-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | MEN1 4566/4885ALDH1A1 190/4885TP53 3284/4885 |
| US-20150307461-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | MEN1 4686/4885ALDH1A1 222/4885TP53 2824/4885 |
| US-20140010783-A1 | ANTIVIRAL COMPOUNDS | HAVCR2, EIF2AK2, MAVS | MEN1 4686/4885ALDH1A1 222/4885TP53 2824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.